FDA Peptide Review, MAHA, and What It Means for Tracking Your Protocol

If you follow the peptide space, the regulatory landscape has shifted significantly over the past year. The FDA has been evaluating peptides commonly used in compounding, the MAHA Commission under HHS Secretary Robert F. Kennedy Jr. has flagged weight-loss drugs for assessment, and 503B compounding rules have tightened.

For anyone running a peptide protocol, these changes create real practical questions: Will my compounds still be available? Should I adjust my stack? How do I keep my records organized if my sources or doses change?

Here is a breakdown of what is happening, what it means, and why tracking your protocol is more important now than it has been.

The FDA peptide evaluation

The FDA has been reviewing bulk drug substances used in compounding — including peptides that are widely used by people managing recovery, performance, longevity, and body composition protocols.

Peptides under review or already affected include compounds commonly used for:

• Recovery and tissue repair (BPC-157, TB-500)
• Growth hormone secretion (CJC-1295, Ipamorelin, Tesamorelin)
• Weight management (semaglutide, tirzepatide — now restricted from 503B compounding)
• Cognitive and sleep support (Selank, Semax, DSIP)
• Immune modulation (Thymosin Alpha-1)

The FDA evaluates these compounds through its Bulk Drug Substances Advisory Committee, which determines whether a peptide can continue to be used in compounding based on safety, effectiveness, and manufacturing standards.

Some peptides have already been restricted. Others are under active review. The situation continues to evolve.

The MAHA Commission and weight-loss drugs

When HHS Secretary Kennedy was sworn in, President Trump signed Executive Order 14211 establishing the Make America Healthy Again (MAHA) Commission. Among its stated objectives is assessing "the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors, antipsychotics, mood stabilizers, stimulants, and weight-loss drugs."

While the MAHA Commission's primary focus has been on childhood chronic disease and vaccines, the explicit mention of weight-loss drugs in the executive order has raised questions about the future regulatory environment for GLP-1 medications and peptides used for body composition.

No direct regulatory action has been taken against GLP-1 medications as a result of the MAHA Commission. But the political and regulatory scrutiny around these medications is increasing, and access through compounding has already been restricted.

What this means for peptide users

If you are running a peptide protocol, the practical implications are:

• Compound availability may change — peptides you currently use may become harder to source if they are restricted from compounding
• Your vendor landscape is shifting — some compounding pharmacies are adjusting their catalogs, and pricing may change
• Dose consistency matters more — if you switch sources, concentrations may differ, and your tracking needs to reflect that
• Documentation protects you — having a clear record of what you took, when, and from where is valuable for both personal tracking and conversations with healthcare providers

Why protocol tracking matters now

When the regulatory environment is stable, tracking is useful for optimization. When it is shifting, tracking becomes essential for continuity.

Specifically:

• Stack history preserves what you were running before any changes — compounds, doses, schedules, and phases
• Dose logs create a timeline that shows when transitions happened and how your body responded
• Inventory tracking helps you manage remaining supply and plan ahead if a compound becomes unavailable
• Health charts with body composition and Apple Health data show whether changes in your protocol are affecting outcomes
• Export capability means you can share your history with a provider if you need to transition to a prescribed alternative

If you are using a tool like Peptaflow to manage your protocol, your stack cards, dose history, and inventory data become a portable record of your entire protocol — useful whether you are continuing, adjusting, or transitioning.

What to do now

1. Document your current stack — compounds, doses, schedule, sources. If things change, you will want a baseline.
2. Track your health markers — weight, body fat, sleep, energy. These are the signals that tell you whether a protocol change is working.
3. Stay informed but do not panic — regulatory reviews take time. Not every peptide under evaluation will be restricted.
4. Talk to your prescriber — if you are using peptides through a compounding pharmacy, your provider is the best source for guidance on alternatives if access changes.
5. Export your data — if you are tracking digitally, make sure you have a PDF or CSV export of your protocol history.

The bottom line

The peptide landscape is changing. FDA evaluations, compounding restrictions, and political scrutiny from the MAHA Commission are all contributing to an environment where access, pricing, and availability are less predictable than they were a year ago.

The one thing you can control is your own data. A clear, organized protocol history — stacks, doses, inventory, and health markers — gives you the ability to adapt, communicate with providers, and make informed decisions regardless of what the regulatory environment does next.